A61K 47/6847
The antibody targeting a hormone or a hormone-releasing or -inhibiting factor
Official title: {the antibody targeting a hormone or a hormone-releasing or -inhibiting factor}
A61K47/6847 (The antibody targeting a hormone or a hormone-releasing or -inhibiting factor) appears on 36 US grants and 61 published applications in this corpus.
Search patents in A61K- Granted patents
- 36
- Published applications
- 61
- Assignees
- 39
- Inventors
- 126
- Latest grant
- 25 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 2 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 2 |
| 2014 | 1 | 6 |
| 2015 | 0 | 5 |
| 2016 | 4 | 5 |
| 2017 | 7 | 6 |
| 2018 | 6 | 5 |
| 2019 | 4 | 4 |
| 2020 | 3 | 6 |
| 2021 | 3 | 1 |
| 2022 | 0 | 3 |
| 2023 | 0 | 2 |
| 2024 | 0 | 1 |
| 2025 | 1 | 4 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Materials and methods for treating stress-related disorders and cancer25 Mar 2025US 12,258,395 B2University of Florida Research Foundation, Inc.
- Poly(vinyl alcohol) nanocarriers5 Oct 2021US 11,135,309 B2The Regents of the University of California
- Targeted delivery of drugs to the myometrium via polypeptides that bind to the oxytocin receptor23 Mar 2021US 10,952,964 B2The University of Newcastle
- Anti-CXCR4 antibodies and antibody-drug conjugates23 Feb 2021US 10,927,178 B2Pfizer Inc.
- Antibody-drug conjugates and immunotoxins15 Dec 2020US 10,864,278 B2Oncomatryx Biopharma, S.L.
- Glp1r agonist-tethered gdf8 antibody conjugates and uses thereof16 Jul 2026US 2026/0199503 A1Regeneron Pharmaceuticals, Inc.
- Combinations of anti-gip antibodies and incretins and uses thereof19 Mar 2026US 2026/0077054 A1Helicore Biopharma, Inc.
- Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity28 Aug 2025US 2025/0270274 A1Serpentide Inc.
- Materials and methods for treating stress-related disorders and cancer5 Jun 2025US 2025/0179168 A1University of Florida Research Foundation, Inc.
- Anti-egfr antibodies and antibody drug conjugates22 May 2025US 2025/0163159 A1
Most cited
By later US patents
- Anti-CXCR4 antibodies and antibody-drug conjugates17US 9,708,405 B2Pfizer Inc. · 2017
- Photodynamic therapy treatment for eye disease15US 7,320,786 B2Light Sciences Oncology, Inc. · 2008
- Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases15US 9,545,450 B2Amicus Therapeutics, Inc. · 2017
- Anti-EGFR antibodies and antibody drug conjugates10US 9,493,568 B2AbbVie Inc. · 2016
- Method for stimulating proliferation of colon cells using POMC.sub.76-1036US 5,547,940 ALudwig Institute for Cancer Research · 1996